|
简介：JQ1 compound是一种 BET bromodomain 抑制剂，抑制 BRD4(1/2) 的 IC50 分别为 77 nM 和 33 nM。 物理化学性质：密度 | 1.3±0.1 g/cm3 | 沸点 | 610.4±65.0 °C at 760 mmHg | 分子式 | C23H25ClN4O2S | 分子量 | 456.988 | 闪点 | 322.9±34.3 °C | 精确质量 | 456.138672 | PSA | 97.61 | LogP | 4.49 | 外观性状 | white to beige | 蒸汽压 | 0.0±1.7 mmHg at 25°C | 折射率 | 1.657 | 储存条件 | 2-8°C | 水溶解性 | DMSO: soluble20mg/mL, clear |
详细介绍：中文名称： | (S)-(+)-2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-基)乙酸叔丁酯 | 中文别名： | （+）-JQ1 抑制剂;(S)-(＋)-2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4];(S)-(+)-2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-6-基)乙酸叔丁酯;(S)-(+)-叔丁基
2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-f][1,2,4]噻唑并[4,3-a][1,4]二氮杂革-6-基)乙酸酯;(S)-2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-基)乙酸叔丁酯;2,4-二氯呋喃并[3,2-D]嘧啶 | 英文名称： | JQ1 compound | 英文别名： | (S)-tert-Butyl
2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate;(+)-JQ-1;(S)-(+)-Tert-butyl
2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4];(+)?-?JQ-?1;(＋)-JQ1;(S)-(+)-Tert-butyl
2;(S)-(+)-Tert-butyl
2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)aceta...;(S)-(+)-Tert-butyl
2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate;(S)-tert-Butyl
2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno-[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate;6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic
acid,;JQ1;(6s)-6-(2-Tert-Butoxy-2-Oxoethyl)-4-(4-Chlorophenyl)-2,3,9-Trimethyl-6,7-Dihydrothieno[3,2-F][1,2,4]triazolo[4,3-A][1,4]diazepin-10-Ium;(S)-JQ1;3mxf;4flp;CHEMBL1957266;JQ-1;SureCN881227;UNII-1MRH0IMX0W;6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic
acid, 4-(4-chlorophenyl)-2,3,9-trimethyl-, 1,1-dimethylethyl ester, (6S)-;JQ1
compound;Bromodomain Inhibitor, (+)-JQ1;1MRH0IMX0W;(S)-(+)-tert-Butyl
2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate;(S)-te | CAS号： | 1268524-70-4 | 分子式： | C23N4O2SCLH25 | 分子量： | 456.99 | 详细描述： | Medlife，致力于提供高品质、高性价比小分子化合物的产品。 小分子化合物大量库存，提供超过2万种的抑制剂、激动剂、拮抗剂等产品，是药物及疾病研究的重要原料供应商。 (+)-JQ-1 是一种
BET bromodomain 抑制剂，抑制 BRD4(1/2)，IC50 分别为 77 nM/33 nM。 |
参考文献：[1].
Filippakopoulos P, et al. Selective inhibition of BET bromodomains. Nature.
2010 Dec 23;468(7327):1067-73. [2]. Matzuk MM,
et al. Small-molecule inhibition of BRDT for male contraception. Cell. 2012 Aug
17;150(4):673-84. [3]. Peirs S, et
al. Targeting BET proteins improves the therapeutic efficacy of BCL-2
inhibition in T-cell acute lymphoblastic leukemia. Leukemia. 2017 Feb 3. [4]. T?gel L, et
al. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or
MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal
Cancer Cells. Mol Cancer Ther. 2016 Jun;15(6):1217-26. [5]. Sahni JM,
et al. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of
Triple-negative Breast Cancers through the Suppression of Aurora Kinases. J
Biol Chem. 2016 Nov 4;291(45):23756-23768. [6]. Nakamura Y,
et al. Targeting of super-enhancers and mutant BRAF can suppress growth of
BRAF-mutant colon cancer cells via repression of MAPK signaling pathway. Cancer
Lett. 2017 Aug 28;402:100-109. [7].
Bhattacharyya S, et al. Altered hydroxymethylation is seen at regulatory
regions in pancreatic cancer and regulates oncogenic pathways. Genome Res. 2017
Nov;27(11):1830-1842. [8]. Lv B, et
al. Enhancement of adenovirus infection and adenoviral vector-mediated gene
delivery by bromodomain inhibitor JQ1. Sci Rep. 2018 Aug 1;8(1):11554. doi: 10.1038/s41598-018-28421-x. [9]. Huang X, et
al. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant
Solid Tumors. Cell. 2018 Sep 20;175(1):186-199.e19. doi:
10.1016/j.cell.2018.08.058. Epub 2018 Sep 13. 产品技术规格说明书，仅做参考使用。
|
